Biotech

After picking up $100 million in venture capital cash earlier this month, Karius is adding another feather to its cap with a breakthrough designation from the FDA.

Biogen's CEO may have been celebrating “turning a corner” last month, but it looks like the drugmaker's early-stage pipeline hasn't gotten the message yet.

Johnson & Johnson is shelling out $850 million to buy Proteologix, getting hold of a young roster of bispecific immunology meds including a phase 1-ready asset that targets TSLP.

The startup May Health has gathered $25 million in funding to help continue clinical studies of its less invasive, outpatient procedure for addressing

Thermo Fisher Scientific has put forward a DNA-based test that it says can offer much more precise identification of blood and its potential

Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets, while

Bayer's masterplan for its OASIS program is coming together, with the German drugmaker posting phase 3 data that suggests it could challenge Astellas for a recently unlocked menopause market.

Welcome to this week's Chutes & Ladders, our ro

On the heels of a groundbreaking FDA approval for a major medtech, a Silicon Valley startup is shaping up to be a possible competitor.

Having stacked all its chips on the idiopathic pulmonary fibrosis (IPF) treatment buloxibutid, Vicore Pharma's bet may be paying off.